The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2018 | Unanswered questions in lung cancer immunotherapy
There are many areas of uncertainty surround immunotherapy, which require further exploration in the coming years. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, discusses some of the most pertinent issues, including resistance mechanisms and the sequencing of therapies. Prof. Hirsch also highlights the need for the further study of immunotherapy in the locoregional and localized settings.
